BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

624 related articles for article (PubMed ID: 27905102)

  • 21. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
    Joeckel TE; Lübbert M
    Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
    Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T
    Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.
    Zeidan AM; Davidoff AJ; Long JB; Hu X; Wang R; Ma X; Gross CP; Abel GA; Huntington SF; Podoltsev NA; Hajime U; Prebet T; Gore SD
    Br J Haematol; 2016 Dec; 175(5):829-840. PubMed ID: 27650975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
    Xie M; Jiang Q; Xie Y
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):22-8. PubMed ID: 25042977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group.
    Lübbert M; Suciu S; Hagemeijer A; Rüter B; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Muus P; Pflüger KH; Schaefer HE; Bogatyreva L; Aul C; de Witte T; Ganser A; Becker H; Huls G; van der Helm L; Vellenga E; Baron F; Marie JP; Wijermans PW;
    Ann Hematol; 2016 Jan; 95(2):191-9. PubMed ID: 26596971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review.
    Haumschild R; Kennerly-Shah J; Barbarotta L; Zeidan AM
    J Oncol Pharm Pract; 2024 Jun; 30(4):721-736. PubMed ID: 38509812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes.
    Finelli C; Follo MY; Stanzani M; Parisi S; Clissa C; Mongiorgi S; Barraco M; Cocco L
    Curr Pharm Des; 2016; 22(16):2349-57. PubMed ID: 26960675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.
    Vidal V; Robert G; Goursaud L; Durand L; Ginet C; Karsenti JM; Luciano F; Gastaud L; Garnier G; Braun T; Hirsch P; Raffoux E; Nloga AM; Padua RA; Dombret H; Rohrlich P; Ades L; Chomienne C; Auberger P; Fenaux P; Cluzeau T
    Oncotarget; 2017 Jul; 8(29):47103-47109. PubMed ID: 28514758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
    Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
    Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.
    Jabbour EJ; Garcia-Manero G; Strati P; Mishra A; Al Ali NH; Padron E; Lancet J; Kadia T; Daver N; O'Brien S; Steensma DP; Sekeres MA; Gore SD; Dezern A; Roboz GJ; List AF; Kantarjian HM; Komrokji RS
    Cancer; 2015 Mar; 121(6):876-82. PubMed ID: 25410759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
    Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
    Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience.
    Ozbalak M; Cetiner M; Bekoz H; Atesoglu EB; Ar C; Salihoglu A; Tuzuner N; Ferhanoglu B
    Hematol Oncol; 2012 Jun; 30(2):76-81. PubMed ID: 21387357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.
    Cabezón M; Malinverni R; Bargay J; Xicoy B; Marcé S; Garrido A; Tormo M; Arenillas L; Coll R; Borras J; Jiménez MJ; Hoyos M; Valcárcel D; Escoda L; Vall-Llovera F; Garcia A; Font LL; Rámila E; Buschbeck M; Zamora L;
    Clin Epigenetics; 2021 Jan; 13(1):9. PubMed ID: 33446256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome.
    Apuri S; Al Ali N; Padron E; Lancet JE; List AF; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):211-214. PubMed ID: 28185797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome of therapy-related myeloid neoplasms treated with azacitidine.
    Fianchi L; Criscuolo M; Lunghi M; Gaidano G; Breccia M; Levis A; Finelli C; Santini V; Musto P; Oliva EN; Leoni P; Aloe Spiriti A; D'Alò F; Hohaus S; Pagano L; Leone G; Voso MT
    J Hematol Oncol; 2012 Aug; 5():44. PubMed ID: 22853048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Azacitidine in the 'real-world': an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada.
    Mozessohn L; Cheung MC; Fallahpour S; Gill T; Maloul A; Zhang L; Lau O; Buckstein R
    Br J Haematol; 2018 Jun; 181(6):803-815. PubMed ID: 29767427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical observation of decitabine-treating patients with myelodysplastic syndrome and acute myeloid leukemia].
    Yang H; Zhu HY; Jiang MM; Wang QS; Han XP; Huang WR; Jing Y; Wang SH; Zhang SS; Mei JH; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):121-5. PubMed ID: 23484704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
    Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
    Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
    Beguin Y; Selleslag D; Meers S; Graux C; Bries G; Deeren D; Vrelust I; Ravoet C; Theunissen K; Voelter V; Potier H; Trullemans F; Noens L; Mineur P
    Acta Clin Belg; 2015 Feb; 70(1):34-43. PubMed ID: 25444072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM).
    Bally C; Thépot S; Quesnel B; Vey N; Dreyfus F; Fadlallah J; Turlure P; de Botton S; Dartigeas C; de Renzis B; Itzykson R; Fenaux P; Adès L
    Leuk Res; 2013 Jun; 37(6):637-40. PubMed ID: 23499498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.